裸盖菇素辅助性治疗市场报告：2031 年趋势、预测与竞争分析

全球裸盖菇素辅助性治疗市场前景光明，在丛集性头痛、焦虑症和精神疾病市场都蕴藏着巨大的机会。预计2025年至2031年间，全球裸盖菇素辅助性治疗市场的复合年增长率将达到3.5%。该市场的主要驱动因素包括精神疾病盛行率的上升、合法化和监管的不断变化，以及对迷幻药研发的投入不断增加。

• Lucintel 预测，由于天然衍生的裸盖菇素的流行，天然衍生的裸盖菇素将在整个预测期内保持较大的份额。
• 从应用角度来看，由于精神病护理的应用范围广泛，因此预计精神疾病仍将是最大的细分市场。
• 按地区划分，由于监管发展和合法化，预计北美在预测期内将出现最高增长。

裸盖菇素辅助性治疗市场的新趋势

由于研究的不断发展、监管的变化以及公众对替代性心理健康疗法日益增长的兴趣，裸盖菇素辅助性治疗市场正在经历重大变革。这些趋势凸显了人们对裸盖菇素治疗潜力及其对未来心理健康护理的影响的日益认可。

• 研究和临床试验增加：近年来，研究裸盖菇素疗效的临床试验数量急剧增加。包括约翰霍普金斯大学、伦敦帝国学院和加州大学在内的领先研究机构正在测试裸盖菇素治疗忧郁症、创伤后压力症候群和成瘾的潜力。随着越来越多的研究显示出令人欣喜的结果，主流精神卫生保健机构对裸盖菇素辅助性治疗的接受度可能会提高。越来越多的证据可能会影响政策制定者对迷幻疗法法律体制的考量，有助于扩大市场。
• 监管变化与合法化：裸盖菇素辅助性治疗市场的一个重要趋势是持续的监管变革。在美国，奥勒冈州州决定于2020年将裸盖菇素治疗合法化，开创了先例，包括科罗拉多和华盛顿州在内的其他州也表示有意采取类似措施。此外，加拿大和一些欧洲国家正在考虑制定迷幻疗法的法律规范。随着立法的不断完善，市场可能会更多地获得裸盖菇素辅助性治疗，并将其应用于临床和治疗领域。
• 融入心理健康治疗计画：裸盖菇素辅助性治疗正逐渐融入综合心理健康治疗计画。治疗师开始将裸盖菇素疗程与心理治疗结合，这种模式旨在增强裸盖菇素的治疗效果。这种结合的动力源于有证据表明，裸盖菇素的心理益处在与专家咨询结合使用时会得到放大。随着心理健康专业人士对这种模式的探索，对裸盖菇素辅助性治疗的需求可能会大幅增加，尤其是在治疗创伤后压力症候群 (PTSD) 和难治性忧郁症等复杂心理健康问题方面。
• 迷幻药的社会文化变迁：文化日渐开放，人们越来越愿意接受包括裸盖菇素在内的迷幻药，将其作为精神疾病的有效治疗选择。媒体报导、纪录片和书籍在迷幻药治疗应用的规范化方面发挥了关键作用。这种社会观念的转变正在加速，尤其是在对替代疗法更加开放的年轻一代。随着社会接受度的提高，对迷幻辅助性治疗的需求预计将会增加，这将使其不仅在临床环境中广泛应用，而且在更广泛的人群中得到推广。
• 迷幻疗法提供者的扩张：人们对裸盖菇素辅助性治疗的兴趣日益浓厚，催生了新的疗法提供者，包括私人诊所、研究机构和专业健康中心。这些提供者在临床和疗养场所提供裸盖菇素治疗，并根据患者情况量身定制治疗体验。迷幻辅助性治疗的普及率不断提高，使得这种疗法更加触手可及，尤其是在保险覆盖范围和相关法规不断完善的情况下。我们预计市场服务将更加多样化，从一对一治疗到团体治疗和疗养式体验。

裸盖菇素辅助性治疗的新兴趋势正在再形成市场，它扩大了获取途径，加强了研究，并改变了大众对迷幻药的认知。临床试验的增加、监管的变化以及裸盖菇素被纳入更广泛的心理健康治疗方案，预计将推动全球对裸盖菇素辅助性治疗的接受。如果这些趋势持续下去，市场将迅速扩张，越来越多的患者寻求替代疗法来应对心理健康挑战，进一步推动该领域的创新和投资。

裸盖菇素辅助性治疗市场的最新趋势

全球裸盖菇素辅助性治疗市场正在经历几项重大发展，这些发展推动了市场成长，并改变了心理健康治疗的模式。这些发展受到技术进步、监管变化以及对裸盖菇素治疗潜力的不断深入研究的影响。

• 监管核准与合法化：最重要的进展之一是迈向裸盖菇素治疗用途合法化。 2020年，俄勒冈州成为美国奥勒冈州，其他州也正在考虑采取类似措施。这项监管改革为其他国家和地区的效仿铺平了道路，并有望扩大裸盖菇素辅助性治疗的可近性。
• FDA突破性疗法认定：在美国，FDA已授予裸盖菇素治疗忧郁症的突破性疗法认定。该认定有望加速基于裸盖菇素的治疗方法的开发，加快临床试验，并最终促使FDA核准其在主要医疗机构中使用。
• 裸盖菇素研究投入不断增加：裸盖菇素研究投入不断增加，许多生技公司和研究机构投入资源研究裸盖菇素对精神疾病的影响。约翰霍普金斯大学和伦敦帝国学院等领先的研究机构处于研究的前沿。随着支持裸盖菇素有效性的科学证据不断增多，预计将有更多资金和资源流入该市场。
• 临床试验的全球扩张：裸盖菇素的临床试验正在全球扩展，欧洲、加拿大和澳洲的研究机构正在携手探索其治疗潜力。这种国际扩张不仅加快了药物研发的步伐，也创造了更具协作性的全球研究环境，从而有望加快裸盖菇素疗法的监管核准并使其得到更广泛的应用。
• 迷幻药公司与医疗保健提供者之间的伙伴关係：迷幻药疗法公司与传统医疗保健提供者之间的策略伙伴关係正在兴起。这些合作将促进裸盖菇素疗法融入主流医疗保健体系。扩大这些合作将有助于建立在临床环境中提供裸盖菇素辅助性治疗的基础设施，从而有可能增加患者获得这种前景光明的疗法的机会。

裸盖菇素辅助性治疗市场的最新趋势表明，迷幻辅助性治疗在被广泛接受和应用方面取得了重大进展。监管改革、研究投入的增加以及临床试验的扩大，正在加速裸盖菇素作为精神疾病主流疗法的发展。这些发展正在推动市场快速成长，并为患者、医疗保健提供者和投资者创造新的机会。

目录

第一章执行摘要

第二章 市场概况

• 背景和分类
• 供应链

第三章：市场趋势及预测分析

• 宏观经济趋势与预测
• 产业驱动力与挑战
• PESTLE分析
• 专利分析
• 法规环境

4. 全球裸盖菇素辅助性治疗市场（按类型）

• 概述
• 按类型进行吸引力分析
• 自然：趋势与预测（2019-2031）
• 综合：趋势与预测（2019-2031）

第五章 裸盖菇素辅助性治疗市场（依应用）

• 概述
• 按用途进行吸引力分析
• 丛集性头痛：趋势与预测（2019-2031）
• 焦虑症：趋势与预测（2019-2031）
• 精神疾病：趋势与预测（2019-2031）

第六章 区域分析

• 概述
• 裸盖菇素辅助性治疗市场（按地区）

7. 北美裸盖菇素辅助性治疗市场

• 概述
• 美国裸盖菇素辅助性治疗市场
• 墨西哥的裸盖菇素辅助性治疗市场
• 加拿大裸盖菇素辅助性治疗市场

8. 欧洲裸盖菇素辅助性治疗市场

• 概述
• 德国裸盖菇素辅助性治疗市场
• 法国裸盖菇素辅助性治疗市场
• 西班牙裸盖菇素辅助性治疗市场
• 义大利裸盖菇素辅助性治疗市场
• 英国裸盖菇素辅助性治疗市场

9. 亚太地区裸盖菇素辅助性治疗市场

• 概述
• 日本裸盖菇素辅助性治疗市场
• 印度裸盖菇素辅助性治疗市场
• 中国的裸盖菇素辅助性治疗市场
• 韩国裸盖菇素辅助性治疗市场
• 印尼的裸盖菇素辅助性治疗市场

10. 其他地区裸盖菇素辅助性治疗市场

• 概述
• 中东裸盖菇素辅助性治疗市场
• 南美洲裸盖菇素辅助性治疗市场
• 非洲裸盖菇素辅助性治疗市场

第11章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析
  • 竞争对手之间的竞争
  • 买方的议价能力
  • 供应商的议价能力
  • 替代品的威胁
  • 新进入者的威胁
• 市占率分析

第十二章：机会与策略分析

• 价值链分析
• 成长机会分析
  • 按类型分類的成长机会
  • 按应用分類的成长机会
• 全球裸盖菇素辅助性治疗市场的新趋势
• 战略分析
  • 新产品开发
  • 认证和许可
  • 合併、收购、协议、合作和合资企业

第十三章 价值链主要企业的公司简介

• 竞争分析
• MindMed
• Compass Pathways
• ATAI Life Sciences
• Field Trip
• DemeRx

第十四章 附录

• 图表目录
• 表格一览
• 调查方法
• 免责声明
• 版权
• 简称和技术单位
• 关于我们
• 联络处

The future of the global psilocybin assisted therapy market looks promising with opportunities in the cluster headaches, anxiety disorders and psychiatric disorders markets. The global psilocybin assisted therapy market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are rising prevalence of mental health disorders, growing legalization and regulatory shifts, and increased investment in psychedelic research and development.

• Lucintel forecasts that, within the type category, natural will remain larger segment over the forecast period due to prevalence of naturally occurring psilocybin.
• Within the application category, psychiatric disorders will remain the largest segment due to wider range of applications in psychiatry.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to regulatory developments and legalization.

Emerging Trends in the Psilocybin Assisted Therapy Market

The psilocybin assisted therapy market is undergoing significant changes, driven by evolving research, regulatory shifts, and increased public interest in alternative mental health treatments. These trends highlight the growing recognition of psilocybin's therapeutic potential and its implications for the future of mental health care.

• Growing Research and Clinical Trials: The number of clinical trials investigating the therapeutic benefits of psilocybin has dramatically increased in recent years. Major research institutions such as Johns Hopkins University, Imperial College London, and the University of California are conducting trials on psilocybin's potential to treat depression, PTSD, and addiction. As more studies demonstrate promising results, the acceptance of psilocybin assisted therapy in mainstream mental healthcare is likely to rise. This growing body of evidence will likely influence policymakers to consider legal frameworks for psychedelic therapy, thereby boosting market expansion.
• Regulatory Changes and Legalization: A significant trend in the psilocybin assisted therapy market is the ongoing shift in regulations. In the United States, Oregon's 2020 decision to legalize psilocybin therapy set a precedent, with other states such as Colorado and Washington showing interest in similar measures. Additionally, Canada and some European countries are considering regulatory frameworks for psychedelic therapies. As the legal landscape evolves, the market will see broader access to psilocybin-assisted therapies, leading to wider adoption in clinical and therapeutic settings.
• Integration with Mental Health Treatment Programs: Psilocybin-assisted therapy is increasingly being integrated into comprehensive mental health treatment programs. Therapists are beginning to combine psilocybin sessions with psychotherapy, a model that aims to enhance the therapeutic effects of the compound. This integration is driven by evidence suggesting that psilocybin's psychological benefits are amplified when used in conjunction with professional counseling. As mental health professionals explore this model, the demand for psilocybin assisted therapy could significantly increase, particularly in the treatment of complex mental health issues like PTSD and treatment-resistant depression.
• Public and Cultural Shifts Toward Psychedelics: There is a growing cultural shift toward openness about psychedelics, including psilocybin, as viable treatment options for mental health disorders. Media coverage, documentaries, and books have played a crucial role in normalizing the use of psychedelics for therapeutic purposes. This shift in public perception is accelerating, particularly among younger generations who are more open to alternative treatments. As societal acceptance grows, demand for psilocybin assisted therapy is expected to increase, expanding its reach to a wider audience beyond clinical settings.
• Expansion of Psychedelic Therapy Providers: The growing interest in psilocybin assisted therapy has led to the emergence of new therapy providers, including private clinics, research organizations, and specialized wellness centers. These providers are offering psilocybin therapy in both clinical and retreat settings, providing tailored experiences for patients. The increasing availability of psychedelic-assisted therapies is making treatment more accessible, especially as insurance coverage and regulations evolve. The market will see greater diversification in service offerings, ranging from one-on-one therapy to group sessions and retreat-style experiences.

The emerging trends in psilocybin assisted therapy are reshaping the market by expanding access, increasing research, and transforming public perceptions of psychedelics. Growing clinical trials, regulatory changes, and the integration of psilocybin into broader mental health treatment programs are expected to lead to greater acceptance of psilocybin assisted therapy worldwide. As these trends continue, the market is set to experience rapid expansion, with more patients seeking alternative therapies for mental health challenges, which will drive further innovation and investment in the sector.

Recent Developments in the Psilocybin Assisted Therapy Market

The global psilocybin assisted therapy market is experiencing several key developments that are driving growth and transforming the landscape of mental health treatment. These developments are shaped by technological advancements, regulatory changes, and growing research into the therapeutic potential of psilocybin.

• Regulatory Approvals and Legalization: One of the most significant developments is the move toward legalizing psilocybin for therapeutic use. In 2020, Oregon became the first state in the U.S. to legalize psilocybin for therapeutic use, with other states considering similar measures. This regulatory shift is expected to pave the way for other countries and regions to follow suit, expanding access to psilocybin assisted therapy.
• Breakthrough Therapy Designation by the FDA: In the U.S., the FDA granted breakthrough therapy designation to psilocybin for the treatment of depression, a key milestone that signals increased recognition of its therapeutic potential. This designation is accelerating the development of psilocybin-based treatments and is expected to expedite clinical trials, ultimately leading to FDA approval for its use in mainstream medical practices.
• Increased Investment in Psilocybin Research: Investment in psilocybin research is growing, with several biotech companies and research institutions dedicating resources to the study of psilocybin's effects on mental health disorders. Major research organizations like Johns Hopkins University and Imperial College London are at the forefront of these studies. As the body of scientific evidence supporting psilocybin's efficacy continues to grow, more funding and resources are expected to flow into the market.
• Global Expansion of Clinical Trials: Clinical trials for psilocybin are expanding globally, with research institutions in Europe, Canada, and Australia joining the effort to investigate its therapeutic benefits. This international expansion is not only accelerating the pace of discovery but also fostering a more collaborative global research environment, which is likely to result in faster regulatory approvals and broader adoption of psilocybin therapy.
• Partnerships Between Psychedelic Companies and Healthcare Providers: Strategic partnerships between psychedelic therapy companies and traditional healthcare providers are on the rise. These collaborations are facilitating the integration of psilocybin therapy into mainstream healthcare systems. As these partnerships grow, they will help create infrastructure for providing psilocybin assisted therapy in clinical settings, increasing access to this promising treatment for a broader patient population.

The recent developments in the psilocybin assisted therapy market are driving significant progress toward the widespread acceptance and adoption of psychedelic-assisted therapies. Regulatory changes, increased investment in research, and the expansion of clinical trials are accelerating the development of psilocybin as a mainstream treatment for mental health disorders. As these developments unfold, the market is poised for rapid growth, offering new opportunities for patients, healthcare providers, and investors alike.

Strategic Growth Opportunities in the Psilocybin Assisted Therapy Market

The global psilocybin assisted therapy market is evolving rapidly, driven by increasing research into the therapeutic benefits of psilocybin for mental health conditions like depression, PTSD, and anxiety. Psilocybin, a naturally occurring psychedelic compound, is gaining recognition as a potential game-changer in the mental health treatment landscape. As the regulatory environment shifts and more clinical trials validate its benefits, numerous growth opportunities are emerging in key applications. These opportunities are opening up new avenues for the industry, providing a path toward the widespread adoption of psilocybin as a mainstream treatment for various psychological conditions.

• Treatment of Depression: One of the most significant growth opportunities for psilocybin assisted therapy is in the treatment of depression, particularly treatment-resistant depression (TRD). Traditional antidepressants often fail to provide relief for a substantial portion of patients. Psilocybin has shown promise in clinical trials as an effective alternative for TRD, with studies indicating that it can provide long-lasting improvements in mood and emotional well-being. As research continues and regulatory bodies, like the FDA, grant breakthrough therapy designations, psilocybin assisted therapy for depression could become a mainstream option for patients seeking alternatives to conventional antidepressants, creating a new market segment.
• PTSD and Trauma Recovery: Another key growth opportunity lies in psilocybin assisted therapy for PTSD and trauma recovery. Clinical trials and anecdotal evidence have demonstrated that psilocybin can help individuals process traumatic memories, reduce emotional numbing, and alleviate symptoms of PTSD. As mental health professionals increasingly recognize the potential of psychedelics for trauma recovery, psilocybin assisted therapy is likely to be integrated into treatment protocols for PTSD, particularly in military veterans, survivors of sexual assault, and others suffering from trauma. The growing demand for innovative PTSD treatments, alongside promising research, positions psilocybin assisted therapy as a critical tool in this space.
• Addiction Treatment: Psilocybin-assisted therapy also holds promise as a treatment for addiction, particularly alcohol and tobacco use disorders. Research has shown that psilocybin can help individuals break free from addictive behaviors by promoting new perspectives and offering profound emotional and psychological insights. The ability of psilocybin to create lasting behavioral changes, combined with its potential to reduce cravings and anxiety, presents a major growth opportunity for the market. As addiction treatment centers begin to explore and implement psilocybin-based therapies, the demand for these services is expected to grow, creating a new niche for psilocybin therapy within the addiction recovery space.
• Anxiety and End-of-Life Care: Psilocybin-assisted therapy is also showing promise in the treatment of anxiety, particularly for patients facing life-threatening illnesses. Studies have found that psilocybin can reduce anxiety and existential distress in patients with terminal cancer, helping them come to terms with their mortality. As the aging population grows, the demand for effective anxiety and end-of-life care is expected to rise. Psilocybin's ability to facilitate a sense of peace, connectedness, and emotional clarity makes it an increasingly valuable tool in palliative care, offering significant growth potential for psilocybin assisted therapy in the healthcare sector.
• Integration into Mental Health Wellness Programs: As societal acceptance of psychedelic therapies increases, psilocybin assisted therapy is likely to become part of broader mental health and wellness programs. Wellness centers, retreat organizations, and private therapy practices are beginning to explore psilocybin as a tool for improving emotional well-being, fostering self-awareness, and promoting personal growth. Integrating psilocybin into these wellness programs, alongside traditional therapeutic practices like talk therapy, offers a new avenue for growth in the market. This trend could see psilocybin therapy expand beyond clinical settings and into the broader wellness and lifestyle sectors.

These strategic growth opportunities demonstrate the diverse potential applications of psilocybin assisted therapy across various sectors, including mental health, addiction treatment, and wellness. As research continues to validate the therapeutic benefits of psilocybin, its integration into clinical and wellness settings is poised to accelerate. The ongoing regulatory developments and cultural shifts toward the acceptance of psychedelics are further driving the market forward. Together, these opportunities will play a crucial role in shaping the future of psilocybin assisted therapy, making it a mainstream treatment option for a range of mental health conditions.

Psilocybin Assisted Therapy Market Driver and Challenges

The global psilocybin assisted therapy market is shaped by a combination of technological, economic, and regulatory factors. These drivers and challenges will determine the pace at which psilocybin can transition from research to mainstream medical use. Understanding these forces is essential for stakeholders, including pharmaceutical companies, healthcare providers, and policymakers, to navigate the evolving landscape of psychedelic-assisted therapies.

The factors responsible for driving the psilocybin assisted therapy market include:

1. Increasing Clinical Evidence Supporting Psilocybin's Efficacy: One of the primary drivers behind the market's growth is the growing body of clinical evidence that supports the effectiveness of psilocybin for treating various mental health conditions, including depression, PTSD, and addiction. The results from studies conducted by leading research institutions, such as Johns Hopkins University and Imperial College London, show that psilocybin has therapeutic potential for individuals who do not respond to conventional treatments. As these studies continue to yield positive results, more healthcare providers will be likely to adopt psilocybin assisted therapy, expanding its use in clinical practice.

2. Regulatory Shifts Toward Legalization: Regulatory changes are a critical factor driving the expansion of the psilocybin assisted therapy market. In recent years, there has been a noticeable shift in the regulatory landscape, particularly in the United States, with states like Oregon and Colorado legalizing psilocybin for therapeutic use. Additionally, the FDA has granted psilocybin breakthrough therapy status for depression, which accelerates the approval process. As more governments explore the potential benefits of psilocybin in treating mental health conditions, the regulatory environment will continue to evolve, facilitating broader access to psilocybin assisted therapy.

3. Societal Acceptance and Cultural Shift: As societal attitudes toward psychedelics continue to change, there is growing cultural acceptance of psilocybin-assisted therapies. Public figures, documentaries, and media coverage have played a significant role in normalizing the conversation around psychedelics. This cultural shift has led to an increased willingness among patients to explore alternative treatments for mental health issues. With more people seeking non-traditional therapies, psilocybin assisted therapy is positioned to meet this demand, providing a new therapeutic option for individuals who are open to innovative treatments.

4. Growing Mental Health Crisis: The global mental health crisis, exacerbated by factors such as the COVID-19 pandemic and rising stress levels, has created an urgent need for effective mental health treatments. Psilocybin-assisted therapy has emerged as a potential solution for addressing issues such as depression, anxiety, and PTSD, conditions that are often difficult to treat with conventional medications. As the demand for alternative therapies grows, psilocybin offers a new avenue for those seeking relief from chronic mental health conditions, driving the market's expansion.

5. Increasing Investment in Psychedelic Research and Startups: The increasing investment in psychedelic research and the rise of psychedelic startups are also major drivers in the growth of the psilocybin assisted therapy market. Investors are drawn to the potential of psychedelics as therapeutic agents, and the growing number of companies focused on psilocybin research and development is accelerating progress. With more funding, psilocybin therapy will be able to move through clinical trials faster and reach the market sooner, contributing to its wider adoption.

Challenges in the psilocybin assisted therapy market are:

1. Regulatory Hurdles and Legalization Delays: Despite the progress made in certain regions, psilocybin remains illegal in many countries. Regulatory challenges are a significant barrier to widespread adoption, as the legal status of psilocybin affects its availability and research. In regions where psilocybin remains prohibited, companies and researchers face difficulties conducting studies, limiting the overall growth potential of the market.

2. Stigma and Misunderstanding of Psychedelics: The stigma surrounding psychedelics, including psilocybin, remains a significant challenge. Public misconceptions about the safety and efficacy of psilocybin can hinder its acceptance as a legitimate therapeutic option. Changing public perception and overcoming historical biases toward psychedelics will require education, advocacy, and continued positive research findings.

3. Shortage of Trained Therapists: As psilocybin therapy expands, there will be an increasing need for trained therapists who are equipped to guide patients through the psilocybin-assisted treatment process. Currently, there is a shortage of mental health professionals with the specialized skills needed to administer psilocybin therapy safely. The development of training programs and certification standards for psilocybin assisted therapy will be crucial for the market's growth.

The drivers of the psilocybin assisted therapy market, including increasing clinical evidence, regulatory shifts, and growing societal acceptance, are pushing the market toward broader adoption. However, challenges such as regulatory hurdles, stigma, and the shortage of trained therapists remain. As the market continues to evolve, overcoming these challenges will be crucial to ensuring that psilocybin assisted therapy can achieve its full potential as a mainstream treatment for mental health disorders.

List of Psilocybin Assisted Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies psilocybin assisted therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the psilocybin assisted therapy companies profiled in this report include-

• MindMed
• Compass Pathways
• ATAI Life Sciences
• Field Trip
• DemeRx

Psilocybin Assisted Therapy Market by Segment

The study includes a forecast for the global psilocybin assisted therapy market by type, application, and region.

Psilocybin Assisted Therapy Market by Type [Value from 2019 to 2031]:

• Natural
• Synthetic

Psilocybin Assisted Therapy Market by Application [Value from 2019 to 2031]:

• Cluster Headaches
• Anxiety Disorders
• Psychiatric Disorders

Psilocybin Assisted Therapy Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Psilocybin Assisted Therapy Market

The global psilocybin assisted therapy market has witnessed significant advancements in recent years, as increasing research into the therapeutic benefits of psilocybin for mental health disorders has gained momentum. Psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has shown promise in treating conditions such as depression, PTSD, and anxiety. This growing interest in psychedelic-assisted therapies has led to notable developments in key markets such as the United States, China, Germany, India, and Japan. Various countries are exploring the potential of psilocybin for medical use, with evolving regulatory landscapes and breakthroughs in clinical trials contributing to the market's growth.

• United States: The United States has become a leading market for psilocybin assisted therapy, driven by significant advances in both research and regulatory changes. In 2020, Oregon became the first state to legalize psilocybin for therapeutic use, a milestone that has encouraged other states to follow suit. Clinical trials are underway, particularly by organizations such as Johns Hopkins University and MAPS (Multidisciplinary Association for Psychedelic Studies), exploring psilocybin's efficacy in treating PTSD, depression, and addiction. The FDA has granted breakthrough therapy designation to psilocybin for depression, signaling increasing recognition of its therapeutic potential.
• China: In China, psilocybin research is still in its early stages, but there is growing interest in the therapeutic use of psychedelics, including psilocybin. Although psilocybin remains illegal for recreational use, the Chinese government has recognized the potential benefits of psychedelics for treating mental health disorders. Research institutions and biotech companies are increasingly focused on exploring the medical use of psychedelics. While regulatory hurdles remain, growing global interest and the success of clinical trials in other regions could lead to a shift in policy in the coming years, potentially opening the door to psilocybin assisted therapy.
• Germany: Germany is one of the leaders in Europe when it comes to psilocybin research and the potential for legalizing psychedelic-assisted therapies. The country has a strong pharmaceutical and research infrastructure that has supported the growth of clinical trials investigating the use of psilocybin for mental health disorders. German researchers are actively exploring psilocybin's potential for treating depression, anxiety, and PTSD. The government has taken steps toward supporting the medical use of psychedelics, with regulations evolving to potentially allow psilocybin for therapeutic purposes, especially as scientific evidence continues to demonstrate its effectiveness in clinical settings.
• India: India's psilocybin assisted therapy market is still in its infancy, as the country's regulatory environment remains restrictive toward psychedelic substances. However, the increasing global interest in psychedelic research has sparked some discussions within India's scientific community regarding the potential for psilocybin to address mental health issues like depression, addiction, and anxiety. Clinical research is limited, but local organizations are starting to explore partnerships with international firms for trials. Public perception remains cautious, and the path toward legalizing psilocybin assisted therapy in India faces significant regulatory and cultural challenges.
• Japan: Japan has also seen some interest in psilocybin assisted therapy, although it is far behind the United States and Europe in this regard. Psilocybin remains illegal in Japan, but ongoing research into the medical use of psychedelics could potentially shift the regulatory landscape. Japanese researchers have started to examine the compound's effects on mental health, especially depression and anxiety, in controlled settings. The government's approach toward drug regulation is cautious, but the growing body of research in other countries, as well as positive clinical results, may prompt Japan to reconsider its stance on psilocybin assisted therapy in the future.

Features of the Global Psilocybin Assisted Therapy Market

• Market Size Estimates: Psilocybin assisted therapy market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Psilocybin assisted therapy market size by type, application, and region in terms of value ($B).
• Regional Analysis: Psilocybin assisted therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the psilocybin assisted therapy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the psilocybin assisted therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the psilocybin assisted therapy market by type (natural and synthetic), application (cluster headaches, anxiety disorders, and psychiatric disorders), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Psilocybin Assisted Therapy Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Natural: Trends and Forecast (2019-2031)
• 4.4 Synthetic: Trends and Forecast (2019-2031)

5. Global Psilocybin Assisted Therapy Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Cluster Headaches: Trends and Forecast (2019-2031)
• 5.4 Anxiety Disorders: Trends and Forecast (2019-2031)
• 5.5 Psychiatric Disorders: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Psilocybin Assisted Therapy Market by Region

7. North American Psilocybin Assisted Therapy Market

• 7.1 Overview
• 7.4 United States Psilocybin Assisted Therapy Market
• 7.5 Mexican Psilocybin Assisted Therapy Market
• 7.6 Canadian Psilocybin Assisted Therapy Market

8. European Psilocybin Assisted Therapy Market

• 8.1 Overview
• 8.4 German Psilocybin Assisted Therapy Market
• 8.5 French Psilocybin Assisted Therapy Market
• 8.6 Spanish Psilocybin Assisted Therapy Market
• 8.7 Italian Psilocybin Assisted Therapy Market
• 8.8 United Kingdom Psilocybin Assisted Therapy Market

9. APAC Psilocybin Assisted Therapy Market

• 9.1 Overview
• 9.4 Japanese Psilocybin Assisted Therapy Market
• 9.5 Indian Psilocybin Assisted Therapy Market
• 9.6 Chinese Psilocybin Assisted Therapy Market
• 9.7 South Korean Psilocybin Assisted Therapy Market
• 9.8 Indonesian Psilocybin Assisted Therapy Market

10. ROW Psilocybin Assisted Therapy Market

• 10.1 Overview
• 10.4 Middle Eastern Psilocybin Assisted Therapy Market
• 10.5 South American Psilocybin Assisted Therapy Market
• 10.6 African Psilocybin Assisted Therapy Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Psilocybin Assisted Therapy Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 MindMed
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Compass Pathways
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 ATAI Life Sciences
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Field Trip
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 DemeRx
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us

List of Figures

• Figure 1.1: Trends and Forecast for the Global Psilocybin Assisted Therapy Market
• Figure 2.1: Usage of Psilocybin Assisted Therapy Market
• Figure 2.2: Classification of the Global Psilocybin Assisted Therapy Market
• Figure 2.3: Supply Chain of the Global Psilocybin Assisted Therapy Market
• Figure 2.4: Driver and Challenges of the Psilocybin Assisted Therapy Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Psilocybin Assisted Therapy Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Psilocybin Assisted Therapy Market ($B) by Type
• Figure 4.3: Forecast for the Global Psilocybin Assisted Therapy Market ($B) by Type
• Figure 4.4: Trends and Forecast for Natural in the Global Psilocybin Assisted Therapy Market (2019-2031)
• Figure 4.5: Trends and Forecast for Synthetic in the Global Psilocybin Assisted Therapy Market (2019-2031)
• Figure 5.1: Global Psilocybin Assisted Therapy Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Psilocybin Assisted Therapy Market ($B) by Application
• Figure 5.3: Forecast for the Global Psilocybin Assisted Therapy Market ($B) by Application
• Figure 5.4: Trends and Forecast for Cluster Headaches in the Global Psilocybin Assisted Therapy Market (2019-2031)
• Figure 5.5: Trends and Forecast for Anxiety Disorders in the Global Psilocybin Assisted Therapy Market (2019-2031)
• Figure 5.6: Trends and Forecast for Psychiatric Disorders in the Global Psilocybin Assisted Therapy Market (2019-2031)
• Figure 6.1: Trends of the Global Psilocybin Assisted Therapy Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Psilocybin Assisted Therapy Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Psilocybin Assisted Therapy Market (2019-2031)
• Figure 7.2: North American Psilocybin Assisted Therapy Market by Type in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Psilocybin Assisted Therapy Market ($B) by Type (2019-2024)
• Figure 7.4: Forecast for the North American Psilocybin Assisted Therapy Market ($B) by Type (2025-2031)
• Figure 7.5: North American Psilocybin Assisted Therapy Market by Application in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Psilocybin Assisted Therapy Market ($B) by Application (2019-2024)
• Figure 7.7: Forecast for the North American Psilocybin Assisted Therapy Market ($B) by Application (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Psilocybin Assisted Therapy Market (2019-2031)
• Figure 8.2: European Psilocybin Assisted Therapy Market by Type in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Psilocybin Assisted Therapy Market ($B) by Type (2019-2024)
• Figure 8.4: Forecast for the European Psilocybin Assisted Therapy Market ($B) by Type (2025-2031)
• Figure 8.5: European Psilocybin Assisted Therapy Market by Application in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Psilocybin Assisted Therapy Market ($B) by Application (2019-2024)
• Figure 8.7: Forecast for the European Psilocybin Assisted Therapy Market ($B) by Application (2025-2031)
• Figure 8.8: Trends and Forecast for the German Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Psilocybin Assisted Therapy Market (2019-2031)
• Figure 9.2: APAC Psilocybin Assisted Therapy Market by Type in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Psilocybin Assisted Therapy Market ($B) by Type (2019-2024)
• Figure 9.4: Forecast for the APAC Psilocybin Assisted Therapy Market ($B) by Type (2025-2031)
• Figure 9.5: APAC Psilocybin Assisted Therapy Market by Application in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Psilocybin Assisted Therapy Market ($B) by Application (2019-2024)
• Figure 9.7: Forecast for the APAC Psilocybin Assisted Therapy Market ($B) by Application (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Psilocybin Assisted Therapy Market (2019-2031)
• Figure 10.2: ROW Psilocybin Assisted Therapy Market by Type in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Psilocybin Assisted Therapy Market ($B) by Type (2019-2024)
• Figure 10.4: Forecast for the ROW Psilocybin Assisted Therapy Market ($B) by Type (2025-2031)
• Figure 10.5: ROW Psilocybin Assisted Therapy Market by Application in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Psilocybin Assisted Therapy Market ($B) by Application (2019-2024)
• Figure 10.7: Forecast for the ROW Psilocybin Assisted Therapy Market ($B) by Application (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Psilocybin Assisted Therapy Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Psilocybin Assisted Therapy Market
• Figure 11.2: Market Share (%) of Top Players in the Global Psilocybin Assisted Therapy Market (2024)
• Figure 12.1: Growth Opportunities for the Global Psilocybin Assisted Therapy Market by Type
• Figure 12.2: Growth Opportunities for the Global Psilocybin Assisted Therapy Market by Application
• Figure 12.3: Growth Opportunities for the Global Psilocybin Assisted Therapy Market by Region
• Figure 12.4: Emerging Trends in the Global Psilocybin Assisted Therapy Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Psilocybin Assisted Therapy Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Psilocybin Assisted Therapy Market by Region
• Table 1.3: Global Psilocybin Assisted Therapy Market Parameters and Attributes
• Table 3.1: Trends of the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 3.2: Forecast for the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Psilocybin Assisted Therapy Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 4.4: Trends of Natural in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 4.5: Forecast for Natural in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 4.6: Trends of Synthetic in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 4.7: Forecast for Synthetic in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Psilocybin Assisted Therapy Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 5.4: Trends of Cluster Headaches in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 5.5: Forecast for Cluster Headaches in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 5.6: Trends of Anxiety Disorders in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 5.7: Forecast for Anxiety Disorders in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 5.8: Trends of Psychiatric Disorders in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 5.9: Forecast for Psychiatric Disorders in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Psilocybin Assisted Therapy Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Psilocybin Assisted Therapy Market (2025-2031)
• Table 7.1: Trends of the North American Psilocybin Assisted Therapy Market (2019-2024)
• Table 7.2: Forecast for the North American Psilocybin Assisted Therapy Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Psilocybin Assisted Therapy Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Psilocybin Assisted Therapy Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Psilocybin Assisted Therapy Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Psilocybin Assisted Therapy Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Psilocybin Assisted Therapy Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Psilocybin Assisted Therapy Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Psilocybin Assisted Therapy Market (2019-2031)
• Table 8.1: Trends of the European Psilocybin Assisted Therapy Market (2019-2024)
• Table 8.2: Forecast for the European Psilocybin Assisted Therapy Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Psilocybin Assisted Therapy Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Psilocybin Assisted Therapy Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Psilocybin Assisted Therapy Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Psilocybin Assisted Therapy Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Psilocybin Assisted Therapy Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Psilocybin Assisted Therapy Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Psilocybin Assisted Therapy Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Psilocybin Assisted Therapy Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Psilocybin Assisted Therapy Market (2019-2031)
• Table 9.1: Trends of the APAC Psilocybin Assisted Therapy Market (2019-2024)
• Table 9.2: Forecast for the APAC Psilocybin Assisted Therapy Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Psilocybin Assisted Therapy Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Psilocybin Assisted Therapy Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Psilocybin Assisted Therapy Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Psilocybin Assisted Therapy Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Psilocybin Assisted Therapy Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Psilocybin Assisted Therapy Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Psilocybin Assisted Therapy Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Psilocybin Assisted Therapy Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Psilocybin Assisted Therapy Market (2019-2031)
• Table 10.1: Trends of the ROW Psilocybin Assisted Therapy Market (2019-2024)
• Table 10.2: Forecast for the ROW Psilocybin Assisted Therapy Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Psilocybin Assisted Therapy Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Psilocybin Assisted Therapy Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Psilocybin Assisted Therapy Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Psilocybin Assisted Therapy Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Psilocybin Assisted Therapy Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Psilocybin Assisted Therapy Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Psilocybin Assisted Therapy Market (2019-2031)
• Table 11.1: Product Mapping of Psilocybin Assisted Therapy Suppliers Based on Segments
• Table 11.2: Operational Integration of Psilocybin Assisted Therapy Manufacturers
• Table 11.3: Rankings of Suppliers Based on Psilocybin Assisted Therapy Revenue
• Table 12.1: New Product Launches by Major Psilocybin Assisted Therapy Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Psilocybin Assisted Therapy Market